Read 30 October 2026, every figure sourced and dated. FDA lists BPC-157 as nominated and then withdrawn, PubMed has 226 papers on it and none tagged as a trial, and HHS published a draft, non-binding enforcement policy the same day. We cover status, evidence and harms, and nothing about dosing or where to buy.
Whitepill finding
As of 30 October 2026, PubMed holds 226 papers on BPC-157 and none tagged as a clinical trial. FDA's page lists it as nominated and withdrawn. HHS published a draft, non-binding policy that day holding off enforcement on compounding certain peptides, and press reports say BPC-157 is one.
The short version
They sayIt's banned.
FDA lists it as nominated and then withdrawn, which is neither a ban nor an approval, and HHS published a draft, non-binding enforcement policy on 30 October. See the receipt
They sayStudies prove it works.
0 of 226 PubMed papers are tagged as a clinical or randomized trial. See the receipt
They sayIt's lab tested, so it's pure.
91 of 197 completed tests in one commercial tester's window missed its own standard. That is one tester, not a market survey. See the receipt
They sayThe FDA committee approved it.
The advisory committee voted 8 to 6 in favour of adding it to a list on 23 July. A vote advises FDA, and FDA decides. See the receipt
FDA's page on bulk drug substances that may present significant safety risks (content current as of 22 April 2026) lists BPC-157 in a separate table of substances "nominated but withdrawn". That table holds substances that were in Category 2 under the interim policy until the nominators withdrew them. Nothing on that page approves it.
The same page says compounded drugs containing BPC-157 may pose a risk of immunogenicity for certain routes of administration and may involve peptide-impurity complexities. It also says FDA has identified no, or only limited, safety-related information for the proposed routes. In plain terms, FDA says it does not know enough to say it is safe.
HHS published a Federal Register notice (91 FR 68526) announcing a draft "enforcement discretion policy" for compounding with certain peptides. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a listed peptide while FDA develops the 503A bulks list through rulemaking. The notice says the draft is not binding on HHS or the public.
HHS's own Appendix A, read in its policy PDF on 1 November 2026, lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. BPC-157 is first on the list. Press reports from AJMC and BioSpace (secondary) said the same.
What changes in practice is enforcement risk for compounders, not the evidence: PubMed still has no trial-tagged paper on BPC-157. Our Regulatory Wire brief covers the notice in full.
Nothing final. FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, on 23 July 2026 in favor of adding BPC-157 to the 503A bulks list, according to ABC News. Time reported that the committee went against the advice of FDA staff, whose preparatory documents cited limited evidence of effectiveness.
A committee vote advises FDA, and FDA decides. On 30 October 2026 we found no final FDA action on the 503A list, only the separate HHS draft above. Check FDA's page for the current status.
A PubMed search on BPC-157 returns 226 papers (query: ("BPC-157"[tiab] OR "BPC 157"[tiab] OR "Body Protection Compound-157"[tiab])). 55 carry PubMed's loose "humans" tag, which is not the same as a human trial. 0 are tagged as a clinical or randomized trial, and 1 is tagged as a case report.
ClinicalTrials.gov lists 4 interventional studies matching the name, and none has posted results. We have not assessed their design.
For scale only, semaglutide, an approved drug, has 344 tagged trial papers. More trials do not mean safe: ibutamoren mesylate (commonly called MK-677) has 16 tagged trial papers, and FDA still lists it in Category 2, citing a potential for congestive heart failure in certain patients. We cover it in the MK-677 compound check.
Few tagged trials do not mean the compound is harmful or useless; they mean the human record is thin. Claims about what it does in people therefore rest on animal studies and case reports.
Finnrick is a commercial peptide-testing company. Its public BPC-157 page displays 943 tests across 149 vendors between 17 Dec 2024 and 21 Oct 2026. We do not link that page because it names sellers, and Whitepill endorses none and has no relationship with Finnrick.
In the latest 200-test window it displays, 106 passed, 91 failed and 3 were incomplete against its own standard (purity 99.5%+, dose within 35%). So 91 of the 197 completed tests missed that standard. This is one company's recent window and not a survey of the market.
The page does not say how samples were obtained and shows no endotoxin results. Treat it as one dated, commercial data point that supports a simple rule: a label is a claim, not a measurement.
Beyond FDA's stated concerns, the published record is thin, which is the problem: PubMed has 1 case report matching the name. Case reports are not rates of harm, so one report says little about how often anything happens. For comparison, melanotan II, an unapproved tanning peptide, has 11 case reports against 4 tagged trial papers.
If you or someone you know has had a bad reaction to any product, report it to FDA MedWatch. Those reports are how a safety record gets built.
1. Open the regulator's own page and read the date on it. Statuses move; a blog that is two months old may be wrong. 2. Count the human trials yourself: search PubMed with the trial filter, and check ClinicalTrials.gov for studies. 3. "No evidence of harm" and "no evidence" are different sentences. Missing trials mean missing data, not safety. 4. A seller's purity certificate is a claim from the seller. Test results from any one lab are one data point. 5. Take what you read to a licensed clinician, and report any adverse event to FDA MedWatch.
At the bottom of the evidence ladder: resistance training has 3,954 tagged randomized-trial papers, creatine 732, sunscreen 321, and BPC-157 none. English Wikipedia pageviews are a rough measure of curiosity, not of use, and BPC-157's article drew about 308,000 in the year to 30 September 2026.
PubMed counts come from the published query shown beside them (title and abstract terms for the name and its common variants, plus a publication-type tag where stated), read 30 October 2026. They move as papers are indexed, and a different query string gives a different count. ClinicalTrials.gov counts are interventional studies matching the same terms, and each study record was read through the registry's API the same day.
FDA's page was read in full on 30 October 2026, and the HHS notice was read through the Federal Register's own API and text. HHS's policy PDF, including its Appendix A listing the six peptides, was read in a browser on 1 November 2026.
Finnrick's figures are what its BPC-157 page displayed that day, and news and law-firm reports are labelled as secondary where they appear. Nothing on this page is medical advice, and it contains no dosing, protocol or sourcing information by design.
Nothing on FDA's own bulk-substances page approves it. As of that page's content date of 22 April 2026, FDA lists BPC-157 in a table of substances nominated for compounding and then withdrawn, and says it has identified no, or only limited, safety information for the proposed routes. We read that page on 30 October 2026.
On 30 October 2026 HHS published a Federal Register notice of a draft enforcement discretion policy for compounding with certain peptides. It says HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound listed peptides while FDA develops the 503A list. The draft is not binding and is not an approval, and HHS's Appendix A names BPC-157 among six covered peptides.
No. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favor of adding it to the 503A bulks list, according to ABC News and Time. Time reported that the committee went against FDA staff advice. A committee vote is advice to FDA, not a decision.
We cannot say, and neither can the trial record: PubMed has 226 papers on it and 0 tagged as a clinical or randomized trial, as of 30 October 2026. Missing trials mean missing evidence, not proof it does nothing.
FDA says it has identified no, or only limited, safety-related information for the proposed routes and lists immunogenicity and impurity concerns for compounded versions. That is a statement about missing data, not a finding of safety.
One commercial tester, Finnrick, displayed 91 of 197 completed tests missing its own standard in its latest 200-test window on 30 October 2026. It is one company's window under its own standard, not a survey of the market, and its page does not say how samples were obtained.
To FDA MedWatch, FDA's adverse event reporting program, and tell a licensed clinician. Reports are how a safety record gets built.
Read the date on the FDA page, count the trials, and treat a label as a claim. BPC-157 has an FDA page that says it lacks safety information, 0 trial-tagged papers, an advisory vote that went against FDA staff, and, as of today, a draft HHS enforcement policy that is not an approval. Nothing here is medical advice; take it to a licensed clinician.